arha lepu Mai saurin gwajin antigen kit AMRDT109 Plus

Amfani da Niyya
Ana amfani da shi don ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙwayoyin rigakafin IgG da IgM na novel coronavirus a cikin jini na ɗan adam, plasma ko duka jini a cikin vitro.

arha lepu Gwajin antigen kit AMRDT109 Plus Features
Gwajin gaggawa: Kawai na mintuna 15
Aiki mai dacewa ba tare da buƙatar mai nazari ba
Farkon ganewar asali da keɓance abubuwan da ake tuhuma
Rage ƙimar rashin ganewa ta hanyar gwajin nucleic acid

Mai rahusa lepu Mai saurin gwajin antigen kit AMRDT109 Plus Sashen da ya dace
• Sashen Gaggawa
• ICU

• Sashen ilimin huhu
• Sashen Aiki na Cardio-Pulmonary

Mai rahusa lepu Mai saurin gwajin antigen kit AMRDT109 Plus Aikace-aikacen asibiti
Shaida na yanzu suna nuna cewa sabon coronavirus ana yaɗa shi ta hanyar ɗigon ruwa, iska, da hulɗa kai tsaye tare da ɓoye.
• A cikin mutanen da suka kamu da sabon coronavirus (2019-ncov), tsarin garkuwar jiki yana samar da martanin rigakafi ga ƙwayar cuta, yana samar da takamaiman ƙwayoyin rigakafi.Za a iya amfani da ƙayyadaddun ƙwayoyin rigakafin da suka dace don tantance kamuwa da cuta tare da sabon coronaviruses.

Kunshin
25 Gwaji/akwati

Lepu Colloidal Gold 2019-nCov Antibody Rapid Test Kit AMRDT109 Plus NUFIN AMFANI
Ana amfani da shi don gano ƙimar sabon coronavirus (SARS-CcV-2) antigen a cikin samfuran swab na hanci na ɗan adam a cikin vitro.
Coronavirus babban iyali ne wanda ya wanzu ko'ina cikin yanayi.Yana da saukin kamuwa ga mutane da dabbobi da yawa.An yi masa suna don fibroids masu kama da corona a saman ƙwayoyin ƙwayoyin cuta.Alamomin asibiti na sabon coronavirus (2019-nCoV) kamuwa da cuta sune zazzabi, gajiya, ciwon tsoka, da bushewar tari, wanda zai iya ci gaba zuwa matsanancin ciwon huhu, gazawar numfashi, har ma da barazanar rayuwa.

Za'a iya amfani da ƙayyadaddun ƙayyadaddun antigen na coronavirus don taimakawa gwajin farko don kamuwa da cutar coronavirus.Wannan kit ɗin na iya yin hukunci game da kamuwa da cutar coronavirus, amma baya bambance SARS-CoV ko kamuwa da cuta ta SARS-CoV-2.